Skip to main content

Table 2 IL12 and IL18 polymorphisms in hemodialysis patients with a titre of antibodies to surface antigen of hepatitis B virus ≤ 10 UI/L (Group I) and > 10 UI/L (Group II)

From: Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients

Variable

Group I (n = 207) n (%)

Group II (n = 311) n (%)

OR (95 % CI)

P value

Genotype frequencies (n, %) expected by Hardy-Weinberg equilibrium, Group I; Group II

IL12A rs568408

GG

157 (75.8)

220 (70.7)

1.00

 

152 (73.5); 222 (71.5)

GA

41 (19.8)

86 (27.7)

0.67 (0.44 – 1.02)

0.059

51 (24.4); 81 (26.1)

AA

9 (4.4)

5 (1.6)

2.52 (0.83 – 7.70)

0.094

4 (2.0); 7 (2.4)

GA/AA

50 (24.2)

91 (29.3)

0.77 (0.51 – 1.15)

0.199

P = 0.213; P = 0.783

IL12B rs3212227

AA

129 (62.3)

193 (62.1)

1.00

 

130 (62.8;) 198 (63.6)

AC

70 (33.8)

110 (35.4)

0.95 (0.65 - 1.38)

0.796

68 (32.9); 100 (32.3)

CC

8 (3.9)

8 (2.6)

1.50 (0.55 - 4.10)

0.433

9 (4.3); 13 (1.4)

AC/CC

78 (37.7)

118 (37.4)

0.99 (0.69 - 1.42)

0.952

P = 0.783; P = 0.421

IL18 rs360719

TT

118 (57.0)

160 (51.4)

1.00

 

123 (59.4); 160 (51.4)

TC

83 (40.1)

126 (40.5)

0.89 (0.62 – 1.29)

0.544

73 (35.4); 126 (40.5)

CC

6 (2.9)

25 (8.0)

0.32 (0.13 – 0.82)

0.009

11 (5.4); 25 (8.0)

TC/CC

89 (43.0)

151 (48.6)

0.80 (0.56 – 1.14)

0.214

P = 0.330; P = 1.000

  1. A significant result (a sample power 72.7%) is indicated using bold font.